Ask AI
ESMO 2025 Lung Cancer

CME

Key Studies in Lung Cancer: Independent Conference Coverage of ESMO 2025

European Learners: 1.50 EBAC® CE Credit

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: December 16, 2025

Expiration: June 15, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Reck M, Girard N, Nadal E, et al. Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: Interim analysis (IA) of the phase II MDT-BRIDGE study. Presented at: 2025 European Society for Medical Oncology Meeting; October 17-21, 2025. Abstract LBA65.
  2. Wang S, Bian D, Guo Q, et al. Surgery versus radiotherapy after induction therapy with serplumimab combined with chemotherapy for unresectable stage IIIB-IIIC non-small cell lung cancer: a randomized controlled, open-label, phase 2 trial. Presented at: 2025 European Society for Medical Oncology Meeting; October 17-21, 2025. Abstract 1818MO.
  3. Lu S, Yang F, Jiang Z, et al. Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONi-6). Presented at: 2025 European Society for Medical Oncology Meeting; October 17-21, 2025. Abstract LBA4.
  4. Jänne PA, Planchard D, Kobayashi K, et al. FLAURA2: Exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC. Presented at: 2025 European Society for Medical Oncology Meeting; October 17-21, 2025. Abstract LBA77.
  5. Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391:1486-1498.
  6. Zhang L, Fang WF, Wu L, et al. Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase III OptiTROP-Lung04 study. Presented at: 2025 European Society for Medical Oncology Meeting; October 17-21, 2025. Abstract LBA5.
  7. Mok T, Yu HA, Lim SM, et al. Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. Presented at: 2025 American Society of Clinical Oncology Meeting; May 30- June 3, 2025. Abstract 8506.
  8. Le X, Kim TM, Dong X, et al. Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study. Presented at: 2025 European Society for Medical Oncology Meeting; October 17-21, 2025. Abstract LBA75.
  9. Popat S, Yamamoto N, Girard N, et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1. Presented at: 2025 European Society for Medical Oncology Meeting; October 17-21, 2025. Abstract LBA74.
  10. Sevabertinib prescribing information. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2025.
  11. Zongertinib prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2025
  12. Wermke M, Lau S, Moskovitz MT, et al. Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study. Presented at: 2025 European Society for Medical Oncology Meeting; October 17-21, 2025. Abstract 2757O.
  13. Mountzios G, Sun L, Cho BC, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025;393:349-361.
  14. Paulson KG, Lau SC, Ahn MJ, et al. Safety and survival update of tarlatamab with anti–PD-L1 as first-line maintenance after chemo-immunotherapy for extensive-stage small cell lung cancer: DeLLphi-303 ph1b trial. Presented at: 2025 World Conference on Lung Cancer; September 6-9, 2025. Abstract OA13.01.
  15. Peters S, Dziadziuszko R, Kalinka E, et al. DAREON®-8: A phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC). Presented at: 2025 European Society for Medical Oncology Meeting; October 17-21, 2025. Abstract 2759MO.